Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders

Gadgeel, S. M.Soria, J. C.Felip, E.Cobo, M.Lu, S.Syrigos, K.Lee, K. H.Goker, E.Georgoulias, V.Li, W.Guclu, S.Isla, D.Ardizzoni, A.Dupuis, N.Gibson, N.Kraemer, N.Buehnemann, C.Solca, F.Ehrnrooth, E.Goss, G.2019-10-272019-10-2720170959-80491879-0852https://hdl.handle.net/11454/32468European-Cancer-Organisation (ECCO) European Cancer Congress -- JAN 27-30, 2017 -- Amsterdam, NETHERLANDSeninfo:eu-repo/semantics/closedAccessSecond-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term respondersConference Object72S185S185WOS:000417650200582Q1